Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

127-07-1 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Hydroxyurea Manufacturer/High quality/Best price/In stock
Cas No: 127-07-1
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
High purity Various Specifications Hydroxyurea CAS:127-07-1
Cas No: 127-07-1
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
CHemwill -- Hydroxyurea
Cas No: 127-07-1
USD $ 1.0-1.0 / Metric Ton 1 Metric Ton 1-500 Metric Ton/Day Chemwill Asia Co., Ltd. Contact Supplier
Cas No: 127-07-1
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
127-07-1 CH4N2O2 Hydroxyurea
Cas No: 127-07-1
No Data 10 Gram 1 Kilogram/Day HENAN SUNLAKE ENTERPRISE CORPORATION Contact Supplier
Hot sale 127-07-1 Hydroxyurea with best price
Cas No: 127-07-1
USD $ 1000.0-1500.0 / Kilogram 1 Kilogram 100 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier
Hydroxyurea Manufacturer 127-07-1 For Anticancer
Cas No: 127-07-1
No Data 10 Gram 10000 Metric Ton/Month Hubei XinRunde Chemical Co., Ltd Contact Supplier
Hydroxyurea ,127-07-1
Cas No: 127-07-1
No Data 1 Metric Ton 1 Metric Ton/Day Henan Tianfu Chemical Co., Ltd. Contact Supplier
Manufacturer Supply Hydroxyurea in stock
Cas No: 127-07-1
No Data 1 Kilogram 1000 Kilogram/Month Shaanxi Mingqi Chemical Co., Ltd Contact Supplier
Cas No: 127-07-1
No Data 20 Gram 300 Metric Ton/Month Hubei Jusheng Technology Co., Ltd., Contact Supplier

127-07-1 Usage

Purification Methods

Recrystallise hydroxyurea from absolute EtOH (10g in 150mL). Note that the rate of solution in boiling EtOH is slow (15-30minutes). It should be stored in a cool dry place, but some decomposition could occur after several weeks. [Deghenghi Org Synth Coll Vol V 645 1973.] It is very soluble in H2O and can be crystallised from Et2O. [Kfod Acta Chem Scand 10 256 1956, Beilstein 3 IV 170.]


An anti-neoplastic - inhibits ribonucleoside reductase and DNA replication. A potential therapy for sickle cell anemia which involves the nitrosylation of sickle cell hemoglobin. Horseradish peroxidase catalyzes nitric oxide formation from hydroxyurea in the presence of hydrogen peroxide.

Production method

It is produced through the reaction between ethyl carbamate and hydroxylamine hydrochloride. The sodium hydroxide solution was cooled to 20-25 ℃. Add alternately under stirring of urethane and hydroxylamine hydrochloride and react at 25-28 ℃ for 16h. Use hydrochloric acid to neutralize to a pH of 6.5-7, control the temperature be not exceeding 25 ℃. Then apply concentration under reduced pressure, filtered hot and the filtrate was cooled to below 0 ℃ to precipitate our the crystal, filter, wash crystal with ice water, and dry to give crude hydroxyurea with the yield of about 65%. After refining, we can obtain pharmaceutical grade hydroxyurea.

Air & Water Reactions

Water soluble.

Adverse reactions, contraindications and the influence of drugs

Myelosuppression was dose-limiting toxicity. Hydroxyurea may cause neutropenia and thrombocytopenia which will disappear at 1 to 2 weeks after discontinuation of the drug; sometimes there may be gastrointestinal reactions, rash, and difficulty in urinating, renal tubular injury as well as testicular atrophy and teratogenesis; there are occasional cases of symptoms of central nervous system and hair loss. It has been also reported that it can cause drug-induced fever which is reproducible under repeated administration. Patients who have allergies, platelets being less than 50 × 109/L, chickenpox, shingles and various kinds of serious infections should be disabled. Pregnant and lactated women should also be disabled. Hydroxyurea can reduce the extent of 5-FU’s being converted into the active metabolite therefore it should be cautious when being taken together. When using hydroxyurea, we should be cautious if need to administrate barbiturates, antipsychotics and anesthetics; when hydroxyurea is combined with allopurinol, colchicine, probenecid for the treatment of gout, the dose of the above drugs should be adjusted. Avoid viral vaccination during treatment. The patients can only be subject to vaccination after discontinuing the drug for three months to one year. Upon taking hydroxyurea sheet, you should appropriately increase the fluid intake amount to increase the amount of urine and excretion of uric acid. The patients should also be subject to regular monitoring of white blood cells, platelets, blood urea nitrogen, uric acid level and inosine concentrations.

Chemical Properties

Off-White Crystalline Solid


It belongs to anti-metabolic anti-cancer drugs with its major role in the proliferation of cells in G1 and S phase. It also had delayed effect on G1/S interface. It is a cell-specific drug.
It can be applied to biochemical studies.
Through the formation of free nitric oxide, it binds to the tyrosine of the enzyme active site, leaving the nucleoside reductase inactivated. This hampers the synthesis of deoxynucleotide. It is clinically used for the treatment of chronic myelogenous leukemia as well as being used to treat metastatic ovarian cancer, head and neck primary squamous cell carcinoma and intractable psoriasis. The good belongs to anticancer drugs.

Drugs and clinical application

Hydroxyurea is a kind of anti-cancer drug for the treatment of chronic myeloid leukemia. At as early as the 1920s, it had been observed that hydroxyurea can cause the rabbits to produce megaloblastic cell similar as pernicious anemia and can inhibit leukocyte generation. In 1963 it had been found of its inhibitory effect on murine leukemia L1210. Hydroxyurea can induce bacteria to produce a toxic molecule itself to achieve the purpose of killing bacteria.
Hydroxy urea is a kind of nucleoside diphosphate reductase inhibitor and can inhibit the reduction from nucleotide to deoxynucleotide, interfering with the biosynthesis of purine and pyrimidine bases and selectively blocking the DNA synthesis. It can also cause partial inhibition of the conversion of ribonucleotides into deoxyribonucleotides. However, it has no blocking effect on RNA and protein synthesis. Hydroxyurea belongs to cycle specific drugs and is sensitive to S phase cell and can induce the hematologic remission of chronic myeloid leukemia. Compared with an alkylating agent busulfan and melphalan, it causes low incidence of secondary leukemia. The myelosuppressive effects of hydroxyurea will last for several days to several weeks which is easier to control compared with the alkylating agent. Clinically hydroxyurea is suitable or the treatment of chronic myeloid leukemia, acute lymphocytic and acute non-lymphocytic leukemia accompanied with high cell count, idiopathic thrombocythemia, polycythemia vera, prevention of retinoic acid syndrome in acute myeloid leukemia and treatment of sickle cell anemia with frequent episodes of pain. In addition, hydroxyurea have a certain effect on the treatment of head and neck cancer, recurrent metastatic ovarian cancer, renal cancer and so on.

Chemical Properties

It appears as white needle-like crystals with the melting point being 70-72 ℃ (decomposition) or 141 ℃ (decomposition). It is easily soluble in hot water and ethanol, slightly soluble in cold ethanol, insoluble in ether, benzene. It is unstable when coming across water or heat. It is odorless and tasteless.


antineoplastic, inhibits ribonucleoside diphosphate reductase


Adult usual dose:
1. chronic myeloid leukemia, usually the starting dose is daily 20~30mg/kg body weight, take 1 times or 2 times through oral administration; when white cells counts decreases to 10 × 109/L or less, reduce the dose to about 20mg/kg body weight daily with maintained oral administration or changed to oral intermittent administration.
2 for the treatment of head and neck cancer and ovarian cancer; the dose should be 60~80mg/kg body weight each time, or ??2000~3000mg/m2 (body surface area) with oral administration once every three days. Administrate it alone or in combination with radiotherapy.
This information is edited by Xiongfeng Dai from Chemicalbook.

Fire Hazard

Flash point data for Hydroxyurea are not available; however, Hydroxyurea is probably combustible.

General Description

Odorless or almost odorless white to off-white crystalline solid. Tasteless.

Reactivity Profile

An amide. Amides/imides react with azo and diazo compounds to generate toxic gases. Flammable gases are formed by the reaction of organic amides/imides with strong reducing agents. Amides are very weak bases (weaker than water). Mixing amides with dehydrating agents such as P2O5 or SOCl2 generates the corresponding nitrile. The combustion of these compounds generates mixed oxides of nitrogen (NOx).

127-07-1 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
Sigma (H8627)  Hydroxyurea  98%, powder 127-07-1 H8627-100G 12,109.50CNY Detail
Sigma (H8627)  Hydroxyurea  98%, powder 127-07-1 H8627-25G 3,983.85CNY Detail
Sigma (H8627)  Hydroxyurea  98%, powder 127-07-1 H8627-10G 2,215.98CNY Detail
Sigma (H8627)  Hydroxyurea  98%, powder 127-07-1 H8627-5G 1,208.61CNY Detail
Sigma (H8627)  Hydroxyurea  98%, powder 127-07-1 H8627-1G 362.70CNY Detail
USP (1332000)  Hydroxyurea  United States Pharmacopeia (USP) Reference Standard 127-07-1 1332000-200MG 4,588.74CNY Detail
Sigma-Aldrich (Y0000119)  Hydroxycarbamide  European Pharmacopoeia (EP) Reference Standard 127-07-1 Y0000119 1,880.19CNY Detail
Alfa Aesar (A10831)  Hydroxyurea, 98%    127-07-1 25g 2651.0CNY Detail
Alfa Aesar (A10831)  Hydroxyurea, 98%    127-07-1 5g 754.0CNY Detail
Alfa Aesar (A10831)  Hydroxyurea, 98%    127-07-1 1g 162.0CNY Detail
TCI America (H0310)  Hydroxyurea  >97.0%(N) 127-07-1 25g 1,350.00CNY Detail
TCI America (H0310)  Hydroxyurea  >97.0%(N) 127-07-1 5g 520.00CNY Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017


1.1 GHS Product identifier

Product name hydroxyurea

1.2 Other means of identification

Product number -
Other names Hydroxycarbamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:127-07-1 SDS

127-07-1Upstream product

127-07-1Downstream Products

127-07-1Related news

Clinical studyCutaneous ulcers associated with Hydroxyurea (cas 127-07-1) therapy09/30/2019

Hydroxyurea is an antitumoral drug mainly used in the treatment of Philadelphia chromosome-negative myeloproliferative syndromes and sickle-cell disease. Ulcers represent a rare but severe long-term adverse effect of hydroxyurea therapy.Hydroxyurea-induced ulcers are often multiple and bilateral...detailed

Real-life experience with Hydroxyurea (cas 127-07-1) in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent09/29/2019

We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, a Southern European country exposed to intense recent flux migration from endemic areas for SCD. We evaluate the impact of hydroxyurea on a total of 652 pediatric and adult patients from 33 Reference Centers f...detailed

Case StudyMalleolar Ulceration Induced by Hydroxyurea (cas 127-07-1) Therapy for Chronic Eosinophila09/28/2019

A 59-year-old African American female presented to a plastic surgery office in consultation for a very painful non-healing wound of her right lateral malleolus. An incisional biopsy was performed and ultimately a diagnosis of hydroxyurea-induced ulcer was concluded. Descriptions of this entity a...detailed

Acute Hydroxyurea (cas 127-07-1) treatment reduces tubular damage following bilateral ischemia-reperfusion injury in a mouse model of sickle cell disease10/01/2019

Ischemic injury is a primary contributor to the initiation of renal tubular epithelial cell damage in sickle cell disease (SCD). In this study, we investigated the effects of bilateral ischemia-reperfusion injury, which is a common type of acute kidney injury (AKI), in male and female genetic mo...detailed

p53 mediates Hydroxyurea (cas 127-07-1) resistance in aneuploid cells of colon cancer09/26/2019

Aneuploidy refers to aberrancies in cellular chromosome count, which is prevalent in most human cancers. Chemotherapy is an effective cancer treatment; however, the development of drug resistance is a major concern of conventional chemotherapy. The chemotherapy agent hydroxyurea (HU) targets pro...detailed

Hydroxyurea (cas 127-07-1) embryotoxicity is enhanced in P53-deficient mice09/24/2019

Hydroxyurea, a ribonucleotide reductase inhibitor, is a potent teratogen in mice, causing severe limb and skeletal defects. The exposure of gestation day nine murine embryos to hydroxyurea elicits an early embryonic stress response that involves activation of the P53 transcription factor. The im...detailed

Beliefs about Hydroxyurea (cas 127-07-1) in youth with sickle cell disease09/10/2019

BackgroundHydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adul...detailed

Original ArticlesTargeted Hydroxyurea (cas 127-07-1) Education after an Emergency Department Visit Increases Hydroxyurea (cas 127-07-1) Use in Children with Sickle Cell Anemia09/09/2019

ObjectiveTo evaluate the impact of an initiative to increase hydroxyurea use among children with sickle cell anemia (SCA) who presented to the emergency department (ED).detailed

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields